Author

P. J. M. Valk

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Assay:clinical cohort / trial· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Curti· 1 shared A. Krippner-Heidenreich· 1 shared A. Messikommer· 1 shared A. Theocharides· 1 shared B. A. van der Reijden· 1 shared B. Lowenberg· 1 shared B. M. H. Heuts· 1 shared B. Maru· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Curti

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The neuronal homeobox transcription factor HMX3 is a crucial vulnerability factor in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia

S. Arza-Apalategi, B. M. H. Heuts, S. M. Bergevoet, R. Meering, D. Gilissen, P. W. T. C. Jansen, A. Krippner-Heidenreich, P. J. M. Valk, M. Vermeulen, O. Heidenreich, T. Haferlach, J. H. Jansen, J. H. A. Martens, B. A. van der Reijden

The paper identifies HMX3 as a critical vulnerability in MECOM-negative KMT2A::MLLT3 AML, showing it promotes proliferation and blocks differentiation.

bioRxiv · Nov 7, 2023 · PreprintCancer Biology

Cancer Prognosis According to Parthanatos Features

A. Messikommer, B. Maru, K. Seipel, P. J. M. Valk, A. Theocharides, T. Pabst, M. McKeague, N. W. Luedtke

This study shows that parthanatos, a PARP-1-mediated cell death pathway, is associated with improved survival in AML patients treated with cytarabine and anthracycline.

bioRxiv · May 24, 2021 · PreprintCancer Biology

TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia

C. Lai, J. Vadakekolathu, S. Reeder, S. E. Church, T. Hood, I. Aldoss, J. Godwin, M. J. Wieduwilt, M. Arellano, J. Muth, F. Ravandi, K. Sweet, H. Altmann, G. A. Foulds, F. Stolzel, , S. Rutella

This paper shows TP53 mutations in AML are linked to immune features and improved response to flotetuzumab immunotherapy.

bioRxiv · Feb 28, 2020 · PreprintImmunology